Evidence map›Paper›PMID 36680060›Full record

ArticleViruses2022

Phage K

Susan M Lehman, Rohit Kongari, Adam M Glass, Matthew Koert, Melissa D Ray, Roger D Plaut, Scott Stibitz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Susan M LehmanCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0002-5831-8148
Rohit KongariCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Adam M GlassCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Matthew KoertCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Melissa D RayCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Roger D PlautCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0002-0883-972X
Scott StibitzCenter for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Center for Biologics Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is widespread interest in using obligately lytic bacteriophages ("phages") to treat human bacterial infections. Among

Indexed as

BacteriophagesMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsHumansMiceStaphylococcus aureusTemperatureAnti-Bacterial Agentsbacteriophagephage-host interactionsphage kStaphylococcus aureustemperature-sensitiveUSA300

Identifiers

PMID36680060
PMCPMC9861931
OpenAlexW4313468814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.